This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SUNNYVALE, Calif. and
Feb. 25, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB:AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, and Banyan Biomarkers, the leader in developing
in vitro diagnostic products to detect TBI, today announced that the companies will be making a joint poster presentation
March 6-7, 2013 at The 3
rd Annual Traumatic Brain Injury (TBI) Conference in
Washington, DC (
www.tbiconference.com). The poster is entitled "Mesencephalic astrocyte-derived neurotrophic factor (MANF) neuroprotection from necrotic and apoptotic cell death in rat cortical cultures."
"MANF significantly inhibited caspase and calpain-mediated cellular processes of cell death and conferred overall neuroprotection in our cellular model systems of TBI," said Dr.
Juan Martinez, Director of Scientific Operations at Banyan Biomarkers. "This neuroprotection indicates therapeutic potential based on well-defined biochemical pathway inhibition. We look forward to working with Amarantus to further develop MANF's therapeutic potential in TBI."
About Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)
MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (Programmed Cell Death). Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (in response to injury or disease), via the unfolded protein response. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF, and is initially focusing on the development of MANF-based protein therapeutics. MANF's current lead indication is Parkinson's disease with additional focus on Traumatic Brain Injury (TBI). Future indications may include myocardial infarction and certain rare and ultra-rare orphan diseases where MANF is currently being evaluated.